Carcinoembryonic antigen (CEA), first described by Gold & Freedman (1965) , is the most widely studied tumour marker. Antibodies against this antigen have proved to be of clinical value in the radioimmunoassay of human circulating CEA (Neville & Cooper, 1976) and also for the location of tumours using the technique of radio-immunolocalisation (RIL) (Begent, 1985) .
CEA is immunologically a complex macromolecule expressing both protein and carbohydrate determinants (Rogers, 1983) . Extensive studies with polyclonal and monoclonal antibodies have demonstrated two broad groups of specificity; those attributed to epitopes which are unique to CEA and those which are also expressed on other glycoproteins (Primus et al., 1983) . Of the many crossreactions which have been reported, the most extensively studied are ascribed to the CEA-like antigens -NCA-1 (Von Kleist et al., 1972) , (Burtin et al., 1973) and normal biliary glycoprotein (Svenberg, 1976) . Cross-reactions with circulating cells (Dillman et al., 1984) and with components of liver, as demonstrated by immunohistochemical techniques, however, have been less well characterised yet these reactions may give rise to non-specific accumulation of antibodies resulting in higherbackgrounds in RIL studies.
Monoclonal antibodies (MAbs) are particularly useful reagents for studying the detailed antigenic expression of CEA. Moreover, since they bind to discrete structures (epitopes) on the CEA molecule, they can be selected for reactivity with the CEAspecific regions of the glycoprotein.
In order to select monoclonal antibodies for clinical assessment, it is important to characterise the relatedness and tissue specificity of the epitopes that they recognise. In this paper, we describe the combined use of epitope analysis, binding studies and immunohistochemistry to map distinct regions of the CEA glycoprotein and identify potentially useful antibodies.
Materials and methods
Purified CEA was prepared from metastases of colonic tumour as previously described (Rogers et al., 1983) . Radio-iodination to a specific activity of 6 pCi pg -1 was carried out by the iodogen method (Fraker & Speck, 1978) . Dilution buffer was prepared as a 0.15 M sodium phosphate buffer, pH 7.4, containing 0.1% bovine serum albumin. The studies at low ionic strength were carried out in 0.02 M Tris-HCl buffer at pH 7.4.
Immunisation schedule
Monoclonal antibodies MA/200 and H58 were raised against purified CEA and HT29 colon tumour cells respectively as previously described (Rogers et al., 1983; Rogers et al., 1984) . The remaining 13 MAbs (Table I) were raised against heat-treated CEA using the following procedure.
One milligram of purified CEA was heated at 85'C for 35min in 0.05M phosphate buffer (pH7) at a concentration of 1 mg ml-1. After mixing with 1 ml of 10% aqueous potassium aluminium sulphate (alum), the pH was adjusted with constant stirring to 6.5-7 by dropwise addition of NaOH solution. After stirring at room temperature for 30min the resulting precipitate was washed three times in saline. It was then mixed with 1010 formalised Bordetella pertussis (kindly supplied by Wellcome Research Laboratories). Three different immunisation schedules were used (see Table I ).
Spleen cells from the immunised mice were then fused with either SP2/0-Ag 14 or P3-NS/1-Ag4-1 myeloma cells (Flow Laboratories, UK) as previously described (Rogers et al., 1984) Affinity constants were determined from inhibition data by the method of Scatchard as previously described (Rogers et al., 1983 On the basis of epitope analysis alone, it was concluded that at least six unrelated regions of the CEA glycoprotein were capable of reacting with different groups of monoclonal antibodies ( Figure   3 ).
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Immunohistochemical analysis
The results of the immunohistochemical analyses are summarised in (Figure 4b) . Seven of the anti-CEA MAbs, MA/200, IC12, E12D4, B4B7, 1H6, 2G8 and H58, however, reacted with polymorphonuclear neutrophils ( Figure 4c ) and with the exception of 1H6 and B4B7, they also stained components of liver (Figure 4d-f 
Discussion
The aim of the present work has been to characterise monoclonal antibodies against CEA prior to their evaluation as tumour markers for radioimmunolocalisation of tumours. In this study we have raised most of the MAbs against heat-treated CEA which was mixed with alum and used formalin-treated Bordetella pertussis as adjuvant. Our experience suggests that such a procedure gives a higher proportion of hybridomas producing CEA-specific antibodies. Using heat-treated CEA for immunisation, however, raises the possibility that antibodies may be directed at artefacts of CEA produced by heat. Routinely formalin-fixed sections, being exposed to a temperature of up to 65°C during processing could give rise to such artefacts. It is unlikely that our antibodies would recognise such artefacts since they were initially screened using unheated CEA. Nevertheless, to confirm this we have compared formalin-fixed and un-fixed cryostat tissue sections (Judd & Britten, 1982) of both tumour and normal tissues which were exposed to temperatures over the range 37-85°C for up to 8 h. No differences in either the intensity or distribution of the reaction was discerned with these sections compared with controls maintained at room temperature. Antibodies which cross-react with human erythrocytes or polymorphonuclear neutrophils have been shown to be unsuitable for RIL on account of an increased accumulation in liver and spleen (Dillman et al., 1984) and possibly a reduced uptake by tumour. In this study we have investigated these cellular cross-reactions by immunohistochemistry since such cells are widespread in colonic tumours and may also be present in the normal tissue sections examined. The epitopes involved in these reactions are attributed to true cross-reactions arising from structural similarities with regions of the CEA glycoprotein since all the MAbs react strongly with purified CEA. The cross-reactions noted with erythrocytes, however, were not due to the known blood group A or precursor H antigen specificities (Rogers, 1983) , since all antibodies were subjected to an agglutination test to exclude such antibodies from this study. Reactivity with polymorphonuclear neutrophils, on the other hand, is likely to be due, in part, to normal cross-reacting antigen (NCA) (Bordes et al., 1975; Burtin & Fondaneche, 1979 the NCA reactivity could be reliably quantitated by radioimmunoassay. Using the latter technique MA/200 and IC12 gave 9 and 4% cross-reactivity respectively with purified NCA. Five of the MAbs which cross-reacted with polymorphonuclear neutrophils also reacted with components of liver. However, the differential antibody specificity for bile canaliculi, Kupffer cells and bile duct epithelium, would suggest that they recognise different epitopes. Reactivity in liver may be due to biliary glycoprotein-like cross-reactivity which has been studied in connection with anti-CEA specificity (Svenberg, 1976) . The differential expression of these glycoproteins could therefore explain the staining patterns observed with different MAbs.
Although the method of epitope analysis used in this study is reproducible, differences in binding affinity between MAbs could affect the percentage blocking obtained. To minimise this we have used saturating amounts of both antibodies in each assay. The method therefore provides reasonable evidence about epitope relatedness. The validity of this approach, however, is further strengthened by the ability of any given MAb to block itself. Moreover, there was a high degree of correlation between epitope relatedness and the immunohistochemical specificity of the antibodies as shown in Figure 3 .
The effect of low ionic strength buffer has been included in this study to distinguish those antibodies which bind more weakly under normal physiological conditions and may therefore be less suitable for localisation (Haskell et al., 1983) . Of the fifteen MAbs, six responded fo a change in the buffer suggesting that they recognised epitopes which are sensitive to structural perturbations brought about by a change in ionic strength. Moreover, we have shown that specific and cross-reactive epitopes on CEA may be ion-sensitive.
The combined strategy adopted in the present study, involving epitope analysis and immunohistology, has allowed a number of CEA-specific and cross-reactive antibodies to be identified which are clearly different in terms of the epitopes which they recognise. This is important since it provides an opportunity of using mixtures of different antibodies to overcome possible heterogeneity of CEA epitope expression within tumours and between different patients. The six CEA-specific antibodies obtained in this study, iBi, IH12, F3C1O, F3D9, F3E3 and A5B7 are currently undergoing further evaluation for possible use in RIL.
